Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label immunogenicity and safety study of 2-dose Gardasil 9 in Chinese girls aged 9-14 years versus 3-dose Gardasil 9 in Chinese women aged 20-26 years
CTR20221250Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 3 more (3 arms), sponsored by Merck & Co. Primary endpoint: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 cLIA antibody titers. Started Jul 2022; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on CTR20221250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221250.